Case report

Pulmonary amyloidosis complicated with pulmonary hemosiderosis, diagnosed with bronchoscopy

Naruhiko Ogo a, Toyoshi Yanagihara a,*, Ryota Nishimura a, Hiroshi Mannoji b, Reiko Yoneda c, Masayasu Hayashi d, Ayaka Egashira a, Tatsuma Asoh a, Takashige Maeyama a

a Department of Respiratory Medicine, Hamanomachi Hospital, Fukuoka, 810-8539, Japan
b Department of Cardiovascular Medicine, Hamanomachi Hospital, Fukuoka, 810-8539, Japan
c Department of Pathology, Hamanomachi Hospital, Fukuoka, 810-8539, Japan
d Department of Hematology, Hamanomachi Hospital, Fukuoka, 810-8539, Japan

ARTICLE INFO

Keywords:
Pulmonary amyloidosis
Pulmonary hemosiderosis
Multiple myeloma
Amyloid tongue

ABSTRACT

We describe a case of an 82-year-old Japanese woman with pulmonary amyloidosis and hemosiderosis associated with multiple myeloma. She had a background of end-stage renal failure of unknown etiology and had been on maintenance dialysis for 2 years. She complained of exertional dyspnea for four months. High-resolution CT of the chest revealed diffuse ground-glass opacities with mosaic attenuation, consolidation in the left lingular lobe, and wedge-shaped, subpleural nodules in the bilateral lower lobes. A transbronchial lung biopsy of the left lingular lobe showed deposition of amorphous, eosinophilic amyloid at the smooth muscle layer of bronchial tissue, with a positive Congo red staining signal in polarized light. Bronchoalveolar lavage fluid was brownish-yellow, and numerous hemosiderin-laden macrophages were detected with Berlin blue staining. From these findings, a diagnosis of pulmonary amyloidosis complicated with pulmonary hemosiderosis was made. Further work-up led to a diagnosis of multiple myeloma. Pulmonary amyloidosis complicated with pulmonary hemosiderosis is a rare disorder and may be underdiagnosed. Physical examination, such as the appearance of the tongue, can assist the diagnosis of systemic amyloidosis. Use of bronchoscopy allows physicians make an early diagnosis of pulmonary amyloidosis that is minimally invasive.

1. Introduction

Amyloidosis is characterized by deposition of insoluble amyloid fibrils, resulting in dysfunction of vital organs [1]. Pulmonary amyloidosis may be localized or may be only one symptom of systemic amyloidosis. Five different forms are known: diffuse alveolar-septal amyloidosis, nodular pulmonary amyloidosis, tracheobronchial amyloidosis, mediastinal lymph node amyloidosis, and pleural amyloidosis [2–5].

Pulmonary hemosiderosis is characterized by repeated episodes of intra-alveolar bleeding leading to abnormal accumulation of iron as hemosiderin in alveolar macrophages [6]. Pulmonary hemosiderosis may occur with diverse conditions such as systemic vasculitis and connective-tissue diseases [7], while some cases, called idiopathic pulmonary hemosiderosis, have no apparent etiology [7,8].

To improve understanding of these diseases, in this article, we describe a patient with pulmonary amyloidosis and hemosiderosis associated with multiple myeloma diagnosed by bronchoscopy.

2. Case presentation

An 82-year-old woman was admitted to the Department of Cardiovascular Medicine at Hamanomachi Hospital for treatment of atrial fibrillation. She complained of exertional dyspnea spanning four months. Her medical history included end-stage renal failure of unknown etiology and maintenance dialysis for two years. Her medication included 2.5 mg of bisoprolol.

She had a temperature of 36.5 °C, blood pressure of 95/59 mmHg, a heart rate of 68 beats per minute, oxygen saturation of 98% under room air. Physical examination revealed slight late inspiratory crackles in both sides of her chest with no peripheral edema. Multiple nodules and tooth indentation were noted on the tongue (Fig. 1).

An echocardiogram showed a decreased left ventricular ejection fraction of 41%. Myocardial biopsy was performed, but there were no specific features. The patient underwent electrical cardioversion, and the atrial fibrillation returned to sinus rhythm.
The patient was then referred to the Department of Respiratory Medicine for abnormal chest imaging. High-resolution CT of the chest revealed diffuse ground-glass opacities (GGO) with mosaic attenuation, consolidation in the left lingular lobe, and subpleural, wedge-shaped nodules in the bilateral lower lobes (Fig. 2). To facilitate diagnosis, bronchoscopy was performed. Bronchoscopy revealed enlarged tortuous submucosal vessels at the main carina and left main bronchus (Fig. 3), suggesting tracheal amyloidosis [9, 10]. A transbronchial lung biopsy (TBLB) of the left lingular lobe was performed. Microscopic examination of the TBLB showed deposition of amorphous eosinophilic amyloid at the smooth muscle layer of the bronchial tissue (Fig. 4A). Congo red staining displayed a positive signal in polarized light (Fig. 4B and C). Immunohistochemical staining for amyloid P was positive (Fig. 4D). No pathogen or malignancy was detected. From these findings, she was diagnosed with pulmonary amyloidosis. Bronchoalveolar lavage fluid from left B3 was brownish-yellow and numerous hemosiderin-laden macrophages were detected with Berlin blue staining (Fig. 5), indicating chronic alveolar hemorrhage, resulting in pulmonary hemosiderosis. Cytology of the lavage showed alveolar macrophage predominance (99% macrophages and 1% neutrophils).

Additional serological examinations to evaluate the etiology of pulmonary hemorrhage causing hemosiderosis, anti-neutrophil cytoplasmic antibody (ANCA), antinuclear antibody (ANA), and rheumatoid factor (RF), were negative. Therefore, pulmonary hemosiderosis was considered related to pulmonary amyloidosis.

An upper gastrointestinal endoscopy was also performed, and a duodenal biopsy confirmed amyloidosis. In addition, a CT of the body showed soft tissue masses around the hip joints, which were thought to be amyloidosis lesions. These findings suggested systemic amyloidosis.

To investigate the etiology of amyloidosis, further serological examinations were performed. Serum IgG, IgA, and IgM levels were low (380 mg/dL, 19 mg/dL, and 4 mg/dL, respectively). Serum free light-chain analysis showed greatly increased lambda light chain of 28,900 mg/L with kappa light chain of 36.8 mg/L. Serum immunoelectrophoresis showed a monoclonal lambda light-chain peak, and urinary Bence-Jones protein was positive.

Suspecting multiple myeloma, bone marrow examination was performed. Bone marrow examination showed plasma cell neoplasms with lambda light-chain restriction. Flow cytometry analysis of bone marrow

Fig. 1. Oral finding of the patient. Multiple nodules and indentation of the tongue, suggesting tongue amyloidosis.

Fig. 2. Radiological findings of the patient. (A) A chest X-ray image on admission. (B) Chest CT images on admission showing diffuse ground-glass opacities (GGO) with mosaic attenuation, consolidation in the left lingular lobe (arrow), and subpleural, wedge-shaped nodules in the bilateral lower lobes (arrowhead).
cells revealed a CD19<sup>– </sup>CD38<sup>high</sup>CD45<sup>– </sup>CD56<sup>+</sup>CD138<sup>+</sup>cyLambda<sup>+</sup> cell population, which is a typical immunophenotype of myeloma cells. This confirmed the diagnosis of multiple myeloma, λ light chain type, international staging system Stage 3. Chemotherapy of bortezomib, lenalidomide and dexamethasone was initiated, followed by oral ixazomib, lenalidomide, and dexamethasone. Six months after diagnosis, she is still receiving chemotherapy on an outpatient basis.

3. Discussion

We report a case of pulmonary amyloidosis and hemosiderosis associated with multiple myeloma, that was successfully diagnosed with bronchoscopy. As reported, ante mortem diagnosis of pulmonary amyloidosis is challenging. Because pulmonary amyloidosis is mostly asymptomatic, many patients with pulmonary amyloidosis are diagnosed only at autopsy [11]. In fact, among 741 patients with systemic AL amyloidosis reported in a nationwide survey in Japan, only 1.6% were diagnosed by lung biopsy [12]. Further, CT findings of pulmonary amyloidosis are nonspecific; therefore, physicians might not seriously consider amyloidosis in a differential diagnosis. Without a special order from respirologists, it is difficult for pathologists to diagnose pulmonary amyloidosis, especially from small TBLB samples.

In this case, the patient had been aware of gradual shortness of breath for four months, and high-resolution CT of the chest revealed diffuse ground-glass opacities (GGO) with mosaic attenuation, consolidation in the left lingular lobe, and subpleural, wedge-shaped nodules in the bilateral lower lobes four months earlier. Even after the patient underwent electrical cardioversion, and the atrial fibrillation returned to sinus rhythm, her exertional dyspnea remained. The chronic course of the disease was consistent with amyloidosis. Therefore, we considered there was an association between exertional dyspnea and pulmonary amyloidosis. The appearance of the patient’s tongue led us to consider systemic amyloidosis as a differential diagnosis. There are many case reports of tongue amyloidosis with multiple myeloma [13–15], and
amyloid protein generated by myeloma cells [24]. The standard treatment of pulmonary amyloidosis is suppression of the production of clonal antibodies) along with corticosteroids. In this case, the patient was not able to tolerate intense treatment, which had resulted in end-stage renal failure. We thus concluded that the patient was not able to tolerate intense treatment, and we chose ixazomib, lenalidomide, and dexamethasone in consideration of the patient’s condition and compliance.

The effect of ixazomib, a first oral proteasome inhibitor, on multiple myeloma was shown in a double-blind, placebo-controlled, phase 3 trial, which assigned 722 patients who had relapsed and/or who had refractory multiple myeloma, to receive ixazomib plus lenalidomide–dexamethasone (ixazomib group) or a placebo plus lenalidomide–dexamethasone (placebo group) [25]. The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival [25]. From this result, ixazomib was approved for multiple myeloma. Further, this ixazomib, lenalidomide, and dexamethasone regimen showed efficacy with deep responses in 47% of patients with relapsed AL amyloidosis [26]. Thus, ixazomib, lenalidomide, and dexamethasone therapy is a good option to treat AL amyloidosis accompanied with multiple myeloma.

In conclusion, pulmonary amyloidosis complicated with pulmonary hemosiderosis is a rare disorder that may be underdiagnosed. Physical examination, such as appearance of the tongue, can assist diagnosis of systemic amyloidosis. Use of bronchoscopy allows an early diagnosis of pulmonary amyloidosis with minimal invasiveness.

Patient consent for publication
Written, informed consent was obtained from the patient.

Declaration of competing interest
All authors of the manuscript declare that they have no conflicts of interest.

References
[1] A.D. Wechalekar, J.D. Gillmore, P.N. Hawkins, Systemic amyloidosis, Lancet 387 (2016) 2641–2654, https://doi.org/10.1016/S0140-6736(15)01274-X.
[2] P. Milani, M. Basset, F. Rostro, A. Foli, G. Palladini, G. Merlini, The lung in amyloidosis, Eur. Respir. Rev. 26 (2017), https://doi.org/10.1183/16000170.0046-2017.
[3] A. Khoor, T.V. Colby, Amyloidosis of the lung, Arch. Pathol. Lab Med. 141 (2017) 247–254, https://doi.org/10.5858/apra.2016-0102-RA.
[4] H.A. Pickford, Thoracic Cross-Sectional of Amyloidosis, 1997, pp. 351–355.
[5] M. Yamada, N. Takayama, H. Yamakawa, T. Ishiguro, T. Baba, Y. Shimizu, K. Okudela, T. Takemura, T. Oyuga, Amyloidosis of the respiratory system: 16 patients with amyloidosis initially diagnosed ante mortem by pulmonologists, ERJ Open Res. 6 (2020), https://doi.org/10.1183/23120541.00313-2019, 00313-02019.
[6] J. Levy, R.W. Wilmott, Pulmonary Hemosiderosis., Pediatr. Pulmonol. 2 (1986) 384–391, https://doi.org/10.1002/ppul.195020612.
[7] O.C. Ioachimescu, S. Sieber, A. Kotch, Idiopathic pulmonary haemosiderosis revisited, Eur. Respir. J. 24 (2004) 162–170, https://doi.org/10.1183/09031936.04.00116302.
[8] T. Yanagihara, Y. Yamamoto, N. Hamada, K. Suzuki, S. Ogata-Suetsugu, E. Harada, T. Tagawa, M. Fujiwara, M. Hashisako, J. Fukuzuo, Y. Nakaniishi, Recurrent idiopathic pulmonary hemosiderosis after long-term remission presented with Sjogren’s syndrome: idiopathic no more? Respir. Med. Case Rep. 25 (2018) 68–72, https://doi.org/10.1016/j.rscr.2018.06.013.
[9] X. Lu, B. He, G. Wang, B. He, L. Wang, Q. Chen, Bronchoscopic diagnosis and treatment of primary tracheobronchial amyloidosis: a retrospective analysis from China, BioMed Res. Int. 2017 (2017), https://doi.org/10.1155/2017/3425812.
[10] M.L. Serrano-Fernández, P. Álvarez-Maldonado, G. Arísti-Urista, A. Valero-Gómez, R. Ciceró-Sabido, C.N.P. Redondo. Narrow-band imaging bronchoscopy in tracheobronchial amyloidosis, J. Bronchol. Interv. Pulmonol. 21 (2014) 267–270, https://doi.org/10.1097/LBR.0000000000000083.

[11] K. Usavarungsi, E.S. Yi, J.J. Malezszewski, P.J. Kurtin, S. Dasari, J.D. Theis, A. Dispenzieri, J.H. Ryu. Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases, Eur. Respir. J. 49 (2017) 10–13, https://doi.org/10.1183/13993003.02313-2016.

[12] C. Shimazaki, H. Hata, S. Iida, M. Ueda, N. Katoh, Y. Sekijima, S. Ikeda, M. Yazaki, W. Fukushima, Y. Ando. Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan, Intern. Med. 57 (2018) 181–187, https://doi.org/10.2169/internalmedicine.9206-17.

[13] A. Uesugi. Multiple myeloma diagnosed from tongue amyloidosis: a case report, J. Blood Lymph 9 (2019) 1–4, https://doi.org/10.37421/jbl.2019.9.237.

[14] S. Babburi, B. Ramya, R.V. Subramaniam, V. Aparna, G. Srivastava. Amyloidosis of the tongue-report of a rare case, J. Diagn. Res. 7 (2013) 3094–3095, https://doi.org/10.7860/CDJR/2013/7028-3865.

[15] S. Sudhakar, B.P. Kumar, M. Prabhat. Amyloidosis tongue: a case report and review of literature, J. Indian Acad. Oral Med. Radiol. 62 (2010) 1–4, https://doi.org/10.5005/jp-journals-10011-1040.

[16] H. Sato, A. Ono, F. Okada, T. Maeda, Y. Saburi, S. Uraebe, H. Mori. A case of diffuse alveolar septal amyloidosis associated with multiple myeloma, J. Thorac. Imag. 30 (2015), https://doi.org/10.1097/RTI.0000000000000183.

[17] Y. Liu, Z. Jin, H. Zhang, Y. Zhang, M. Shi, F. Meng, Q. Sun, H. Cai. Diffuse parenchymal pulmonary amyloidosis associated with multiple myeloma: a case report and systematic review of the literature, BMC Canc. 18 (2018) 379A, https://doi.org/10.1186/s12885-018-4565-5.

[18] W. Sterlacci, L. Veits, P. Moser, H.J. Steiner, S. Rüscher, H. Jamnig, G. Mikuz. Idiopathic systemic amyloidosis primarily affecting the lungs with fatal pulmonary haemorrhage due to vascular involvement, Pathol. Oncol. Res. 15 (2009) 135–136, https://doi.org/10.1007/s12253-008-9066-4.

[19] Y. Kurahara, K. Tachibana, M. Kitaichi, S. Hayashi. Pulmonary diffuse alveolar septal amyloidosis, Intern. Med. 51 (2012) 1447–1448, https://doi.org/10.2169/internalmedicine.51.7056.

[20] J. Kelbe, L. Santo Tomas, N. Rao. Primary pulmonary lambda light chain (AL) amyloidosis with giant cell reaction misdiagnosed as sarcoidosis, Chest 148 (2015) 379A, https://doi.org/10.1378/chest.2242881.

[21] S.J. Kligerman, T. Henry, C.T. Lin, T.J. Franks, J.R. Galvin. Mosaic attenuation: etiology, methods of differentiation, and pitfalls, Radiographics 35 (2015) 1360–1380, https://doi.org/10.1148/rg.2015140308.

[22] R.A. Yood. Bleeding manifestations in 100 patients with amyloidosis, JAMA, J. Am. Med. Assoc. 249 (1983) 1222, https://doi.org/10.1001/jama.1983.03330340064034.

[23] M. Shenin, W. Xiong, M. Naik, N. Sandorfi. Primary amyloidosis causing diffuse alveolar hemorrhage, J. Clin. Rheumatol. 16 (2010) 175–177, https://doi.org/10.1097/RHU.0b013e3181df8345.

[24] S.V. Rajkumar. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management, Am. J. Hematol. 91 (2016) 719–734, https://doi.org/10.1002/ajh.24402.

[25] P. Moreau, T. Masszi, N. Grzasko, N.J. Baldis, M. Hansson, L. Pour, I. Sandhu, P. Gandy, B.W. Baker, S.R. Jackson, A.-M. Stoppa, D.R. Simpson, P. Gimsing, A. Palumbo, L. Garderet, M. Gavo, S. Kumar, C. Touzeau, F.K. Buaid, J.P. Laubach, D.T. Berg, J. Lin, A. Di Bacco, A.-M. Hui, H. van de Velde, P.G. Richardson, Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma, N. Engl. J. Med. 374 (2016) 1621–1634, https://doi.org/10.1056/nejmoa1516282.

[26] O.C. Cohen, F. Sharpley, J.D. Gillmore, H.J. Lachmann, S. Sachchithanantham, S. Mahmood, M. Fontana, C.J. Whelan, A. Martinez-Nahirro, C. Kyriakou, N. Rabin, R. Kopat, K. Yong, S. Cheesman, R. Shah, P.N. Hawkins, A.D. Wechalekar, Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis, Br. J. Haematol. 189 (2020) 643–649, https://doi.org/10.1111/bjh.16401.